Is bleomycin associated with the development of lung fibrosis?

Bleomycin is indeed associated with the development of lung fibrosis, making it an important consideration in clinical practice. This chemotherapy agent is known for its potential to cause pulmonary toxicity, which can manifest as pneumonitis and ultimately lead to pulmonary fibrosis. The risk of developing lung fibrosis is dose-dependent and can be influenced by the cumulative dose of bleomycin, as well as by individual patient factors such as preexisting lung conditions and the presence of other risk factors such as tobacco use.

Recognizing this association is crucial for healthcare providers when monitoring patients undergoing treatment with bleomycin. They should be vigilant for symptoms indicative of lung damage, including cough, dyspnea, or changes in pulmonary function tests. Regular assessment and counseling about the potential risks can help manage and mitigate the consequences of this serious side effect.